The collaboration aims to bring together Stockholm-based AAX Biotech’s expertise in antibody design and the development of multispecific molecules with Discovery Evolution’s platform for digital antibody discovery and identification of new drug targets.
“Identifying a promising antibody binder is an important starting point – but taking that discovery further requires the right antibody format with the right molecular properties,” says Daniel X. Johansson, CSO and co-founder of AAX Biotech, in a press release.
BREAKING